145 related articles for article (PubMed ID: 37341200)
1. Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population.
Grasic Kuhar C; Gortnar Cepeda T; Kurzeder C; Vetter M
Radiol Oncol; 2023 Jun; 57(2):211-219. PubMed ID: 37341200
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
Ferreira AR; Di Meglio A; Pistilli B; Gbenou AS; El-Mouhebb M; Dauchy S; Charles C; Joly F; Everhard S; Lambertini M; Coutant C; Cottu P; Lerebours F; Petit T; Dalenc F; Rouanet P; Arnaud A; Martin A; Berille J; Ganz PA; Partridge AH; Delaloge S; Michiels S; Andre F; Vaz-Luis I
Ann Oncol; 2019 Nov; 30(11):1784-1795. PubMed ID: 31591636
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Turkish versions of EORTC QLQ-C30 and BR23 modules in breast cancer patients.
Demirci S; Eser E; Ozsaran Z; Tankisi D; Aras AB; Ozaydemir G; Anacak Y
Asian Pac J Cancer Prev; 2011; 12(5):1283-7. PubMed ID: 21875283
[TBL] [Abstract][Full Text] [Related]
6. Reliability and validity of Amharic version of EORTC QLQ-C30 and QLQ-BR23 modules for assessing health-related quality of life among breast cancer patients in Ethiopia.
Gadisa DA; Gebremariam ET; Ali GY
Health Qual Life Outcomes; 2019 Dec; 17(1):182. PubMed ID: 31830992
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
9. Worsening of rest-activity circadian rhythm and quality of life in female breast cancer patients along progression of chemotherapy cycles.
Sultan A; Choudhary V; Parganiha A
Chronobiol Int; 2017; 34(5):609-623. PubMed ID: 28276853
[TBL] [Abstract][Full Text] [Related]
10. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
Osoba D; Zee B; Pater J; Warr D; Kaizer L; Latreille J
Qual Life Res; 1994 Oct; 3(5):353-64. PubMed ID: 7841968
[TBL] [Abstract][Full Text] [Related]
11. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: Health-related quality of life final analysis from the Florence phase 3 trial.
Meattini I; Saieva C; Miccinesi G; Desideri I; Francolini G; Scotti V; Marrazzo L; Pallotta S; Meacci F; Muntoni C; Bendinelli B; Sanchez LJ; Bernini M; Orzalesi L; Nori J; Bianchi S; Livi L
Eur J Cancer; 2017 May; 76():17-26. PubMed ID: 28262584
[TBL] [Abstract][Full Text] [Related]
12. The Impact of AC and AC-T Chemotherapy's Toxicities on Quality of Life Among Women with Breast Cancer in Ethiopia: A Prospective Patient-Reported Outcomes Study.
Gadisa DA; Wang SH; Yimer G
Breast Cancer (Dove Med Press); 2021; 13():107-132. PubMed ID: 33658844
[TBL] [Abstract][Full Text] [Related]
13. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
[TBL] [Abstract][Full Text] [Related]
14. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
15. A graphical LASSO analysis of global quality of life, sub scales of the EORTC QLQ-C30 instrument and depression in early breast cancer.
Poikonen-Saksela P; Kolokotroni E; Vehmanen L; Mattson J; Stamatakos G; Huovinen R; Kellokumpu-Lehtinen PL; Blomqvist C; Saarto T
Sci Rep; 2022 Feb; 12(1):2112. PubMed ID: 35136160
[TBL] [Abstract][Full Text] [Related]
16. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
Hurvitz SA; Quek RGW; Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke E; Mina LA; Balmaña J; Fasching PA; Bhattacharyya H; Hannah AL; Robson ME; Wardley AM
Eur J Cancer; 2018 Nov; 104():160-168. PubMed ID: 30359909
[TBL] [Abstract][Full Text] [Related]
17. Normative data for the EORTC QLQ-C30 from the Austrian general population.
Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
[TBL] [Abstract][Full Text] [Related]
18. Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: A tertiary care center survey in the western region of Saudi Arabia.
Imran M; Al-Wassia R; Alkhayyat SS; Baig M; Al-Saati BA
PLoS One; 2019; 14(7):e0219093. PubMed ID: 31291302
[TBL] [Abstract][Full Text] [Related]
19. Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore.
Chan A; Lew C; Wang XJ; Ng T; Chae JW; Yeo HL; Shwe M; Gan YX
Health Qual Life Outcomes; 2018 Jan; 16(1):20. PubMed ID: 29351803
[TBL] [Abstract][Full Text] [Related]
20. Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.
Battisti NML; Reed MWR; Herbert E; Morgan JL; Collins KA; Ward SE; Holmes GR; Bradburn M; Walters SJ; Burton M; Lifford K; Edwards A; Robinson TG; Martin C; Chater T; Pemberton KJ; Shrestha A; Brennan A; Cheung KL; Todd A; Audisio RA; Wright J; Simcock R; Green T; Revell D; Gath J; Horgan K; Holcombe C; Winter MC; Naik J; Parmeshwar R; Gosney MA; Hatton MQ; Thompson AM; Wyld L; Ring A;
Eur J Cancer; 2021 Feb; 144():269-280. PubMed ID: 33373871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
